Literature DB >> 10097618

Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index.

D A Revicki1, N K Leidy, F Brennan-Diemer, C Thompson, A Togias.   

Abstract

The Rhinitis Symptom Utility Index (RSUI) was developed as a preference-based measure of rhinitis symptoms. The RSUI consist of ten questions on the severity and frequency of stuffy or blocked nose, runny nose, sneezing, itching, watery eyes and itching nose or throat over a 14 day period. A cross-sectional survey of 100 adults with allergic rhinitis was completed, with data collected on rhinitis history and severity, physician-rated rhinitis severity, the Rhinitis Quality of Life Questionnaire (RQLQ) and the Health Utilities Index Mark 2 (HUI2). The mean age of the patients was 37 +/- 11 years and 60% were female and 38% had a diagnosis of asthma. A multiplicative multiattribute utility function was developed from patient-derived preferences for different rhinitis-related symptom states. The mean RSUI score for this sample was 0.72 +/- 0.23, with a range of 0.15-1.0. Two week reproducibility of the RSUI was weak (ICC = 0.40). The index differentiated patients by physician-rated severity (p < 0.05) and was correlated 0.35 (p < 0.001) with the HUI2 and -0.67 (p < 0.001) with the RQLQ total score. The RSUI is brief and easy to administer and the results of this study support its reliability and validity. The modest reproducibility reflects the day to day variability of rhinitis. The RSUI may be a useful patient outcome for clinical trials and for cost-effectiveness studies comparing medical treatments for rhinitis.

Entities:  

Mesh:

Year:  1998        PMID: 10097618     DOI: 10.1023/a:1008860113818

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  19 in total

Review 1.  Multi-attribute preference functions. Health Utilities Index.

Authors:  G W Torrance; W Furlong; D Feeny; M Boyle
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

2.  Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire.

Authors:  J Bousquet; J Duchateau; J C Pignat; C Fayol; P Marquis; S Mariz; J E Ware; B Valentin; B Burtin
Journal:  J Allergy Clin Immunol       Date:  1996-08       Impact factor: 10.793

3.  Comparison of powder and aerosolized budesonide in perennial rhinitis: validation of rhinitis quality of life questionnaire.

Authors:  E F Juniper; G H Guyatt; B Andersson; P J Ferrie
Journal:  Ann Allergy       Date:  1993-03

4.  Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis.

Authors:  E F Juniper; G H Guyatt
Journal:  Clin Exp Allergy       Date:  1991-01       Impact factor: 5.018

5.  Ipratropium bromide nasal spray in non-allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life.

Authors:  J W Georgitis; C Banov; P B Boggs; R Dockhorn; J Grossman; D Tinkelman; P Roszko; C Wood
Journal:  Clin Exp Allergy       Date:  1994-11       Impact factor: 5.018

6.  Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis.

Authors:  R P Harvey; C Comer; B Sanders; R Westley; W Marsh; H Shapiro; M Wiener
Journal:  J Allergy Clin Immunol       Date:  1996-06       Impact factor: 10.793

7.  The relationships between nasal hyperreactivity, quality of life, and nasal symptoms in patients with perennial allergic rhinitis.

Authors:  T de Graaf-in 't Veld; S Koenders; I M Garrelds; R Gerth van Wijk
Journal:  J Allergy Clin Immunol       Date:  1996-09       Impact factor: 10.793

8.  Ipratropium bromide aqueous nasal spray for patients with perennial allergic rhinitis: a study of its effect on their symptoms, quality of life, and nasal cytology.

Authors:  E O Meltzer; H A Orgel; E A Bronsky; S R Findlay; J W Georgitis; J Grossman; P Ratner; C C Wood
Journal:  J Allergy Clin Immunol       Date:  1992-08       Impact factor: 10.793

9.  Double-blind study of intranasal ipratropium bromide in nonallergic perennial rhinitis.

Authors:  H M Druce; S L Spector; P Fireman; H Kaiser; E O Meltzer; P Boggs; C C Wood; E P Paluch
Journal:  Ann Allergy       Date:  1992-07

10.  Diary keeping in asthma: comparison of written and electronic methods.

Authors:  M E Hyland; C A Kenyon; R Allen; P Howarth
Journal:  BMJ       Date:  1993-02-20
View more
  29 in total

1.  The use of the Tobit model for analyzing measures of health status.

Authors:  P C Austin; M Escobar; J A Kopec
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

2.  Adjusting distributions of the Health Utilities Index Mark 3 utility scores of health-related quality of life.

Authors:  Jian Sun
Journal:  Qual Life Res       Date:  2003-02       Impact factor: 4.147

Review 3.  The economic burden of allergic rhinitis: a critical evaluation of the literature.

Authors:  Shelby D Reed; Todd A Lee; Douglas C McCrory
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Diagnostic tools in Rhinology EAACI position paper.

Authors:  Glenis Scadding; Peter Hellings; Isam Alobid; Claus Bachert; Wytske Fokkens; Roy Gerth van Wijk; Philippe Gevaert; Josep Guilemany; Livije Kalogjera; Valerie Lund; Joaquim Mullol; Giovanni Passalacqua; Elina Toskala; Cornelius van Drunen
Journal:  Clin Transl Allergy       Date:  2011-06-10       Impact factor: 5.871

5.  Rhinitis Symptom Utility Index (RSUI) in Chinese subjects: a multiattribute patient-preference approach.

Authors:  Phoebe S Y Lo; Michael C F Tong; Dennis A Revicki; Ching Chyi Lee; John K S Woo; Henry C K Lam; C Andrew van Hasselt
Journal:  Qual Life Res       Date:  2006-06       Impact factor: 4.147

6.  Rhinitis in children and adolescents with asthma: Ubiquitous, difficult to control, and associated with asthma outcomes.

Authors:  Alkis Togias; Peter J Gergen; Jack W Hu; Denise C Babineau; Robert A Wood; Robyn T Cohen; Melanie M Makhija; Gurjit K Khurana Hershey; Carolyn M Kercsmar; Rebecca S Gruchalla; Andrew H Liu; Emily Wang; Haejin Kim; Carin I Lamm; Leonard B Bacharier; Dinesh Pillai; Steve M Sigelman; James E Gern; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2018-09-11       Impact factor: 10.793

7.  Rasch analysis in the development of a simplified version of the National Eye Institute Visual-Function Questionnaire-25 for utility estimation.

Authors:  Jonathan W Kowalski; Anne M Rentz; John G Walt; Andrew Lloyd; Jeff Lee; Tracey A Young; Wen-Hung Chen; Neil M Bressler; Paul Lee; John E Brazier; Ron D Hays; Dennis A Revicki
Journal:  Qual Life Res       Date:  2011-08-04       Impact factor: 4.147

8.  Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease.

Authors:  Maureen P M H Rutten-van Mölken; Martine Hoogendoorn; Leida M Lamers
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Development of a preference-based index from the National Eye Institute Visual Function Questionnaire-25.

Authors:  Anne M Rentz; Jonathan W Kowalski; John G Walt; Ron D Hays; John E Brazier; Ren Yu; Paul Lee; Neil Bressler; Dennis A Revicki
Journal:  JAMA Ophthalmol       Date:  2014-03       Impact factor: 7.389

Review 10.  Assessing nasal symptom control.

Authors:  Nkiruka U Erekosima; Rohit K Katial
Journal:  Curr Allergy Asthma Rep       Date:  2009-03       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.